LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Pfizer
Incyte Corporation
GlaxoSmithKline
Amgen
City of Hope Medical Center
Celgene
Duke University
SWOG Cancer Research Network
University of Illinois at Chicago
Pfizer
Altor BioScience
Karyopharm Therapeutics Inc
Amgen
pharmaand GmbH
Altor BioScience
Stemline Therapeutics, Inc.
Hellenic Society of Hematology
Antengene Corporation
Takeda
H. Lee Moffitt Cancer Center and Research Institute
Hackensack Meridian Health
GlaxoSmithKline
Celgene
University of Michigan Rogel Cancer Center
European Society for Blood and Marrow Transplantation
University of Arkansas
University of Arkansas
Merck Sharp & Dohme LLC
Boston VA Research Institute, Inc.
Masonic Cancer Center, University of Minnesota
Merck Sharp & Dohme LLC
Roswell Park Cancer Institute
Novartis
GlaxoSmithKline
Fred Hutchinson Cancer Center
Roswell Park Cancer Institute
Celgene
Novartis
Roswell Park Cancer Institute
University of Maryland, Baltimore
Roswell Park Cancer Institute
Takeda
Celgene
NYU Langone Health
University Health Network, Toronto
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Weill Medical College of Cornell University
Masonic Cancer Center, University of Minnesota
Novartis